Skip to main content

NewImage

Berlin, Germany, and U.S.A. – Epigenomics AG (Frankfurt Prime Standard: ECX, OTC: EPGNY), the German-American cancer molecular diagnostics company, announced today that it has entered into a joint commercialization agreement with Polymedco Inc., a leading provider of colorectal cancer tests in North America. Both companies will jointly commercialize Epi proColon®, Epigenomics’ blood-based test for colorectal cancer (CRC) screening, in North America.

{iframe}http://www.epigenomics.com/en/news-investors/news-media/press-releases/article/epigenomics-und-polymedco-unterzeichnen-kommerzialisierungsvereinbarung-fuer-epi-procolonR-fuer-den-no.html?utm_source=+BioMaryland+Update+10-4-13&utm_campaign=Update+-9%2F17&utm_medium=email{/iframe}

Search

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

BioHealth Innovation will use the information you provide on this form to be in touch with you and to provide updates and marketing.